Commentary
Volume 14:04, 2023

Journal of AIDS & Clinical Research

ISSN: 2155-6113 Open Access

HIV to COVID Ezrin Peptide Therapy: Inhibition of Inflammation and Expansion of Adaptive Antiviral Immunity

Weoerst Bosen*

Department of Health and Social Services, University of the State of Bahia, Salvador, USA

Introduction

The emergence of the COVID-19 pandemic caused by the novel coronavirus SARS-CoV-2 has highlighted the urgent need for effective antiviral therapies and vaccines. In the world of virology, lessons learned from combating other viral infections, such as HIV, can provide valuable insights. One intriguing avenue of research is the potential use of Ezrin Peptide Therapy to inhibit inflammation and expand adaptive antiviral immunity across a range of viral infections, including both HIV and COVID-19 [1,2]. Ezrin, a multifunctional protein involved in cell signaling, has garnered attention for its role in modulating the host immune response. This article explores the potential of Ezrin Peptide Therapy as a novel approach to mitigating inflammation and enhancing adaptive antiviral immunity, with a focus on both HIV and COVID-19 [3].

Description

Ezrin is a member of the ERM (Ezrin-Radixin-Moesin) family of proteins, which act as cytoskeletal linkers and regulators of various cellular processes. While Ezrin's primary function is in maintaining cell structure, recent research has uncovered its crucial role in the immune response. HIV, the Human Immunodeficiency Virus, remains a global health challenge, affecting millions of people worldwide. While much progress has been made in understanding the virus and developing antiretroviral therapies, there are still many aspects of HIV infection that require further investigation. One such aspect is the impact of HIV on the intestinal mucosa and its role in macromolecule translocation through apoptotic leaks and transcytosis. To comprehend the significance of macromolecule translocation in HIV, it is essential to understand the gut-immune axis [4,5]. The intestinal mucosa is not only a physical barrier but also a critical site for immune surveillance and regulation. The mucosal immune system is highly specialized and tightly regulated to balance the protection against pathogens and tolerance towards commensal microorganisms [6].

Conclusion

Ezrin Peptide Therapy represents a promising avenue of research for inhibiting inflammation and expanding adaptive antiviral immunity in the context of viral infections like HIV and COVID-19. By harnessing the immunomodulatory properties of Ezrin, researchers may develop innovative treatments that complement existing antiviral strategies. However, the translation of Ezrin Peptide Therapy from bench to bedside requires extensive preclinical and clinical evaluation to ensure safety and efficacy. As we continue to grapple with viral threats like HIV and COVID-19, exploring unconventional approaches like Ezrin Peptide Therapy is essential in the pursuit of effective antiviral therapies and improved patient outcomes.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Pore, Debasis and Neetu Gupta. "The ezrin-radixin-moesin family of proteins in the regulation of B-cell immune response." *crit rev immunol* 35 (2015).
2. Parameswaran, Neetha, Gospel Enyindah-Asonye, Nayer Bagheri and Neilay B. Shah, et al. "Spatial coupling of JNK activation to the B cell antigen receptor by tyrosine-phosphorylated ezrin." *J Immunol Res* 190 (2013): 2017-2026.
3. Holms, Rupert D. and Ravshan I. Ataullakhanov. "Ezrin peptide therapy from HIV to COVID: Inhibition of inflammation and amplification of adaptive anti-viral immunity." *Int J Mol Sci* 22 (2021): 11688.
4. Aziz, Muhammad, Rawish Fatima and Ragheb Assaly. "Elevated interleukin-6 and severe COVID-19: A meta-analysis." *J Med Virol* 92 (2020): 2283.
5. Lowery, Shea A., Alan Sariol and Stanley Perlman. "Innate immune and inflammatory responses to SARS-CoV-2: Implications for COVID-19." *Cell Host and Microbe* 29 (2021): 1052-1062.
6. Merad, Miriam, Aruna Subramanian and Taia T. Wang. "An aberrant inflammatory response in severe COVID-19." *Cell Host and Microbe* 29 (2021): 1043-1047.

How to cite this article: Bosen, Weoerst. "HIV to COVID Ezrin Peptide Therapy: Inhibition of Inflammation and Expansion of Adaptive Antiviral Immunity." *J AIDS Clin Res* 14 (2023): 956.

***Address for Correspondence:** Weoerst Bosen, Department of Health and Social Services, University of the State of Bahia, Salvador, USA, E-mail: weoerstb@gmail.com*

Received: 03 August, 2023, Manuscript No. jar-23-114966; **Editor Assigned:** 05 August, 2023, PreQC No. P-114966; **Reviewed:** 17 August, 2023, QC No. Q-114966; **Revised:** 22 August, 2023, Manuscript No. R-114966; **Published:** 29 August, 2023, DOI: 10.37421/2155-6113.2023.14.956